olipudase alfa: clinical use

Prescribing considerations

• Treatment should be supervised by a clinician experienced in ASMD or inherited metabolic disease, with facilities to manage severe systemic hypersensitivity.
• Gradual treatment initiation and stepwise infusion are essential because rapid sphingomyelin breakdown can trigger inflammatory reactions and liver-enzyme elevations.
• Consider home infusion only in stable, treatment-tolerant patients after prescriber assessment and with appropriate emergency arrangements.
• Record product name and batch number to maintain biological-medicine traceability.

Contraindications and cautions

• Life-threatening hypersensitivity or anaphylaxis to olipudase alfa or any formulation excipient.
• Exercise particular caution after severe hypersensitivity, previous significant infusion reactions, treatment interruption or suspected reaccumulation of sphingomyelin.

Monitoring

• Check ALT and AST before treatment and closely during gradual initiation or reintroduction after missed treatment.
• Monitor during and after infusion for hypersensitivity, acute-phase and other infusion-associated reactions.
• Consider IgE anti-drug-antibody testing after severe hypersensitivity and IgG testing if clinical response appears to decline.
• Continue routine clinical assessment of ASMD manifestations and treatment response.

Clinical pharmacology

Olipudase alfa is recombinant human acid sphingomyelinase. It reduces accumulated sphingomyelin and is expected to undergo proteolytic degradation into small peptides and amino acids; it is not expected to cross the blood–brain barrier.

Formulation and product differences

• The selected UK product is a white to off-white powder for concentrate in a single-use vial.
• It must be reconstituted with sterile water, diluted with sodium chloride infusion solution and administered intravenously; filtration devices should not be used during preparation.
• The formulation contains L-methionine, phosphate salts, sucrose and a small amount of sodium.

Solution for infusion

Route: Intravenous

Strengths: 20 mg